中国医学前沿杂志（电子版）2024，Vol.16Issue(3)：1-4,4.DOI:10.12037/YXQY.2024.03-01
世界卫生组织对BPaLM方案治疗耐多药结核病指南的解读
Interpretation of the World Health Organization guidelines for BPaLM regimens for the treatment of multidrug-resistant tuberculosis
段鸿飞1
作者信息
- 1. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所结核科,北京 101149
- 折叠
摘要
Abstract
Multidrug-resistant tuberculosis(MDR-TB)remains a significant risk for human health,and the World Health Organization has recently recommended a 6-month treatment regimen(BPaLM)with bedaquiline(Bdq),pretomanid(Pa),linezolid(Lzd)and moxifloxacin(Mfx)to treat MDR-TB.The new regimen not only extend the short-course program to MDR-TB patients,but also apply to tuberculosis with extensive lesions and most extrapulmonary tuberculosis,which is undoubtedly an important event in the treatment of MDR-TB.This article briefly introduces research history,population and considerations of BPaLM regimen.关键词
耐多药/利福平耐药结核病/短程治疗/世界卫生组织Key words
Multidrug-resistant/rifampicin-resistant tuberculosis/Short-course regimen/World Health Organization引用本文复制引用
段鸿飞..世界卫生组织对BPaLM方案治疗耐多药结核病指南的解读[J].中国医学前沿杂志（电子版）,2024,16(3):1-4,4.
